文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

机器人前列腺SBRT中基准点追踪保真度:盆腔淋巴结照射后3次加强与确定性5次治疗的比较

Fiducial tracking fidelity in robotic prostate SBRT: a comparison of a 3-fraction boost following pelvic nodal irradiation and definitive 5-fraction treatment.
PubMed 文献 · Radiat Oncol · 2025-09-30

本研究比较高危前列腺癌患者在接受盆腔淋巴结照射后行3次机器人SBRT加强治疗与低淋巴结转移风险患者行确定性5次SBRT的基准点追踪情况。共405例患者,3次加强组96例,5次组309例。3次加强组无显著基准点追踪丢失(p=0.63),而5次组出现显著进行性追踪丢失(p<0.001)且波动性更高。

要点

  • 盆腔淋巴结照射不影响后续3次SBRT加强的基准点追踪数量与质量。
  • 5次SBRT治疗中基准点追踪随时间进行性丢失且波动性增加。
  • ADT使用、基准点放置至SBRT时间、CTV及治疗频率与追踪变化无显著关联。

核心结论

  • 盆腔淋巴结治疗不影响3次SBRT加强治疗中基准点追踪的数量和质量。
  • 5次SBRT治疗显示基准点追踪随时间进行性丢失和波动性增加。
  • 预处理因素未显著影响两队列的基准点追踪变化,但5次组中ADT使用有波动性增加趋势。
  • 至少放置4个基准点时,单个基准点丢失或波动对追踪系统无临床影响。

研究设计与样本

  • 机构内分析,前瞻性收集接受常规淋巴结放疗后前列腺及精囊腺3次SBRT加强患者的基准点追踪数据。
  • 同时识别接受5次SBRT且淋巴结受累风险低的患者作为对照。
  • 共纳入405例患者,2021年4月至2023年9月治疗,其中5次SBRT组309例(76%),3次加强组96例(24%)。
  • 采用Monte Carlo估计的Fisher精确检验评估基准点追踪丢失,Mann-Whitney检验比较连续变量,Kruskal-Wallis检验和Monte Carlo分析追踪模式,Spearman相关系数和Mann-Whitney检验分析5次治疗中追踪偏差。

主要发现

  • 3次加强治疗组无显著基准点追踪丢失(p=0.63)。
  • 5次治疗组显示显著基准点追踪保真度丢失(p<0.001),表现为一个追踪基准点进行性丢失。
  • 5次治疗组波动性显著高于3次加强组(中位波动性2.4 vs. 0.0,p<0.001)。
  • ADT、基准点放置至SBRT时间、CTV及QOD与每日SBRT在3次或5次治疗中与基准点追踪、波动性均无显著关联。

临床怎么用

  • 对于接受盆腔淋巴结照射后行3次SBRT加强的高危前列腺癌患者,基准点追踪保真度不受影响。
  • 在5次SBRT治疗中应关注基准点追踪的进行性丢失和波动性增加。
  • 确保至少放置4个基准点,单个基准点丢失或波动对追踪系统无临床影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pelvic nodal irradiation is often used for high-risk prostate adenocarcinoma. A commonly used alternative to low dose rate (LDR) brachytherapy, a 3-fraction SBRT boost with fiducial tracking may allow for better coverage of extracapsular extension and macroscopic seminal vesicle invasion. This study evaluates the practical impact of prior pelvic nodal irradiation on fiducial tracking during a subsequent 3-fraction robotic stereotactic body radiation therapy (SBRT) boost for high-risk prostate cancer and compares these outcomes to a cohort of patients undergoing definitive 5-fraction SBRT. METHODS: In this institutional analysis, we prospectively collected fiducial tracking data for patients receiving a 3-fraction boost to the prostate and seminal vesicles after conventional nodal radiation. We also identified patients treated with 5-fraction SBRT with a low risk of nodal involvement. Monte Carlo estimates of the Fisher's Exact Test assessed fiducial tracking loss. Continuous variables within the 5- and 3-fraction cohorts were compared using the Mann-Whitney Test. Changes in fiducial tracking and their association with pre-treatment factors were analyzed through the Kruskal-Wallis test and Monte Carlo for tracking patterns, and Spearman Correlation Coefficient and Mann-Whitney Test for deviations in tracking over 5 fractions. RESULTS: A total of 405 patients were treated from April 2021 to September 2023 with: (1) 5-fraction SBRT (n = 309, 76%), and (2) 3-fraction boost after nodal irradiation (n = 96, 24%). There was no significant fiducial tracking loss over the three-fraction boost treatment regimen that proceeded nodal treatment (p = 0.63). However, there was a significant (p < 0.001) loss of fiducial tracking fidelity as demonstrated by progressive loss of one tracked fiducial over 5-fractions. There was significantly more volatility observed in the 5-fraction versus 3-fraction boost treatment (median volatility 2.4 vs. 0.0, p < 0.001). There were no significant associations between fiducial tracking, independently for 3- or 5-fractions, using either analysis method or volatility for ADT, time from fiducial placement to SBRT, CTV, and QOD vs. daily SBRT. CONCLUSIONS: Pelvic nodal treatment does not affect the quantity/quality of fiducial tracking in 3-fraction treatments. However, 5-fraction treatments showed a progressive loss and increased volatility in fiducial tracking over time. No pre-treatment factors significantly influenced fiducial tracking changes in either cohort, though ADT use trended towards increased volatility in the 5-fraction group. With a minimum of 4 fiducials placed for treatment, the loss/volatility of a single fiducial had no clinical impact on the tracking system.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lischalk JW, Santos VF, Vizcaino B, et al. Fiducial tracking fidelity in robotic prostate SBRT: a comparison of a 3-fraction boost following pelvic nodal irradiation and definitive 5-fraction treatment. Radiat Oncol. 2025. PMID: 41029748. doi:10.1186/s13014-025-02654-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。